EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Role of Antiviral Prophylaxis in Preventing HBV and HDV Recurrence in the Setting of Liver Transplantation

Sara Battistella, Alberto Zanetto iD, Martina Gambato iD, Giacomo Germani, Marco Senzolo, Patrizia Burra iD, Francesco Paolo Russo iD

Viruses · 2023

DOI: 10.3390/v15051037 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Viruses, 2023. Verfasst von Sara Battistella und 6 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Multivisceral Transplant Unit, Azienda Ospedale-Università di Padova, 35128 Padova, Italy. Hauptthemen laut MEDLINE: Liver Transplantation, Hepatitis B, Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatitis B virus (HBV) is a prevalent underlying disease, leading to liver transplantation (LT) for both decompensated cirrhosis and hepatocellular carcinoma (HCC). The hepatitis delta virus (HDV) affects approximately 5–10% of HBsAg carriers, accelerating the progression of liver injury and HCC. The initial introduction of HBV immunoglobulins (HBIG), and then of nucleos(t)ide analogues (NUCs), considerably improved the survival of HBV/HDV patients post-transplantation, as they helped prevent re-infection of the graft and recurrence of liver disease. Combination therapy with HBIG and NUCs is the primary post-transplant prophylaxis strategy in patients transplanted for HBV- and HDV-related liver disease. However, monotherapy with high-barrier NUCs, such as entecavir and tenofovir, is safe and also effective in some individuals who are at low risk of HBV reactivation. To address the problems of organ shortage, last-generation NUCs have facilitated the use of anti-HBc and HBsAg-positive grafts to meet the ever-increasing demand for grafts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver TransplantationHepatitis BCarcinoma, HepatocellularLiver NeoplasmsHumansHepatitis B virusHepatitis Delta VirusAntiviral AgentsHepatitis B Surface AntigensImmunoglobulinsTreatment OutcomeNeoplasm Recurrence, LocalHepatitis B Antibodies

Stichwörter der Autor:innen

HBVHBV prophylaxisHDVliver transplantation

Substanzen

Antiviral AgentsHepatitis B Surface AntigensImmunoglobulinsHepatitis B Antibodies

Autor:innen und Institutionen

  • Gastroenterology and Multivisceral Transplant Unit, Azienda Ospedale-Università di Padova, 35128 Padova, Italy.
  • Department of Surgery, Oncology and Gastroenterology, University of Padua, Via Giustiniani 2, 35128 Padova, Italy.

ORCID-Profile: Alberto Zanetto, Martina Gambato, Patrizia Burra, Francesco Paolo Russo

Zitieren

APA

Battistella, S., Zanetto, A., Gambato, M., Germani, G., Senzolo, M., Burra, P., & Russo, F. P. (2023). The Role of Antiviral Prophylaxis in Preventing HBV and HDV Recurrence in the Setting of Liver Transplantation. Viruses. https://doi.org/10.3390/v15051037

Vancouver

Battistella S, Zanetto A, Gambato M, Germani G, Senzolo M, Burra P, et al. The Role of Antiviral Prophylaxis in Preventing HBV and HDV Recurrence in the Setting of Liver Transplantation. Viruses. 2023. doi:10.3390/v15051037

BibTeX
@article{Battistella2023,
  author = {Battistella, Sara and Zanetto, Alberto and Gambato, Martina and Germani, Giacomo and Senzolo, Marco and Burra, Patrizia and Russo, Francesco Paolo},
  title = {The Role of Antiviral Prophylaxis in Preventing HBV and HDV Recurrence in the Setting of Liver Transplantation},
  journal = {Viruses},
  year = {2023},
  doi = {10.3390/v15051037}
}
Kostenlos starten →